Daptomycin: a novel agent for Gram-positive infections

Bibliography

• ELIOPOULOS GM, WILLEY S, REISZNER E, SPITZER PG, CAPUTO G, MOELLERING RC: In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibi-otic. Antimicrob. Agents Chemother. (1986) 30:532–535.
   PubMed Web of Science ®Google Scholar
• FASS RJ, HELSEL VL: In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimi-crab. Agents Chemother. (1986) 30:781–784.
   PubMed Web of Science ®Google Scholar
• JONES RN, BARRY AL: Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. (1987) 31:625–629.
   PubMed Web of Science ®Google Scholar
• SILVA M, JACOBUS NV, GORBACH SL: In vitro activity of LY146032 against gram-positive bacteria. Diagn. Microbial. Infect. Dis. (1988) 9:79–85.
   PubMed Web of Science ®Google Scholar
• LI T, ZHANG X, OLIVER N, ANDREW T, SILVERMAN J, TALLY FP: In vivo efficacy of daptomycin against systemic infection induced by vancomycin-resistant Enterococcus faecalis (VRE) in the mouse. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (1998). Abstract F–116.
   Google Scholar
• •Daptomycin's efficacy in an animal model of VRE-induced bacteremia.
   Google Scholar
• JACOBUS NV, MCDERMOTT L, LONKS JR, BOYCE JM, SNYDMAN DR: In vitro activity of daptomycin against resistant gram-positive pathogens. Program and Abstracts of the 38th Intel-science Conference on Antimicro-bial Agents and Chemotherapy San Diego, CA, USA (1998). Abstract F–112.
   Google Scholar
• •Daptomycin's in vitro activity against resistant Gram-positive pathogens.
   Google Scholar
• CANEPARI P, BOARETTI M, DEL MAR LLE0 M, SATTA G:Lipoteichoic acid as a new target for activity of antibi-otics: Mode of action of daptomycin (LY146032). Antimicrob. Agents Chemother. (1990) 34:1220–1226.
   PubMed Web of Science ®Google Scholar
• BOARETTI M, CANEPARI P, DEL MAR LLE0 M, SATTA G:The activity of daptomycin on Enterococcus faecium protoplasts: Indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J. Antimicrob. Chemother. (1993) 31:227–235.
   PubMed Web of Science ®Google Scholar
• BOARETTI M, CANEPARI P: Identification ofdaptomycin-binding proteins in the membrane of Enterococcus hirae. Antimicrob. Agents Chemother. (1995) 39:2068–2072.
   PubMed Web of Science ®Google Scholar
• ALBORN WE, JR, ALLEN NE, PRESTON DA: Daptomycindisrupts membrane potential in growing Staphylo-coccus aureus. Antimicrob. Agents Chemother. (1991) 35:2282–2287.
   PubMed Web of Science ®Google Scholar
• ALLEN NE, ALBORN WE, JR, HOBBS JN, JR.: Identificationof membrane potential-dependent amino acid transport by daptomycin. Antimicrob. Agents Chemother. (1991) 35:2639–2642.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ, HERSHBERGER E, MOLDOVAN T: Compara-tive in vitro activity of daptomycin vs. vancomycin, linezolid and Synercid against methicillin-resistant and susceptible staphylococci, vancomycin-intermediate susceptible Staphylococcus aureus (VISA) and vancomycin-susceptible (VS) and resistant enterococci (VRE). Program and Abstracts of the 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (1998). Abstract C–146.
   Google Scholar
• •Daptomycin's in vitro activity against resistant Gram-positive pathogens.
   Google Scholar
• TENOVER FC: Personal communication. NosocomialPathogens Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, USA (February 1998).
   Google Scholar
• DATA ON FILE: Clinical Microbiology Institute, Wilsonville,OR, USA.
   Google Scholar
• DATA ON FILE: Alden Research Laboratory, Holden, MA,USA.
   Google Scholar
• HANBERGER H, NILSSON LE, MAILER R, ISAKSSON B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postanti-biotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob. Agents Chemother. (1991) 35:1710–1716.
   PubMed Web of Science ®Google Scholar
• ••Daptomycin's rapid bactericidal activity in comparison tovancomycin.
   Google Scholar
• VANCE-BRYAN K, LARSON TA, ROTSCHAFER JC, TOSCANO JP: Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (1992) 36:2334–2337.
   PubMed Web of Science ®Google Scholar
• LAMP KC, RYBAK MJ, BAILEY EM, KAATZ GW: In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. (1992) 36:2709–2714.
   PubMed Web of Science ®Google Scholar
• BENSON CA, BEAUDETTE F, TRENHOLM G: Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against Gram-positive organisms. J. Antimicrob. Chemother. (1987) 20:191–196.
   PubMed Web of Science ®Google Scholar
• BLENKHARN JI, DARRELL JH: Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model. Eur. J. Clin. Microbic)]. Infect. Dis. (1989) 8:734–737.
   PubMed Web of Science ®Google Scholar
• EL-MADY A, MORTENSEN JE: The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant E. faecium. Diagn. Microbiol. Infect. Dis. (1991) 14:141–145.
   PubMed Web of Science ®Google Scholar
• FONTANA R, GROSSATO A, LIGOZZI M, TONIN EA: Invitro response to bactericidal activity of cell wall-active antibiotics does not support the general opinion that enterococci are naturally tolerant to these antibiotics. Antimicrob. Agents Chemother. (1990) 34:1518–1522.
   PubMed Web of Science ®Google Scholar
• LOUIE A, BALTCH AL, RITZ WJ, SMITH RP, ASPERILLA M:Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy (1993) 39:302–310.
   PubMed Web of Science ®Google Scholar
• MOBARAKAI N, QUALE JM, LANDMAN D: Bactericidalactivities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. (1994) 38:385–387.
   PubMed Web of Science ®Google Scholar
• STRATTON CW, LIU C, RATNER HB, WEEKS LS: Bacteri-cidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob. Agents Chemother. (1987) 31:1014–1016.
   PubMed Web of Science ®Google Scholar
• VAN DER AUWERA P: Ex vivo study of serum bacteri-cidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob. Agents Chemother. (1989) 33:1783–1790.
   PubMed Web of Science ®Google Scholar
• BUSH LM, BOSCIA JA, WENDELER M, PITSAKIS PG, KAYE D: In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. (1989) 33:1198–1200.
   PubMed Web of Science ®Google Scholar
• HANBERGER H: Pharmacodynamic effects of antibi-otics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. Scand.J. Infect. Dis. (1992) Suppl. 81:1–52.
   Google Scholar
• TRIPODI M-F, ADINOLFI LE, UTILI R, MARRONE A, RUGGIERO G: Influence of subinhibitory concentra-tions of loracarbef (LY 163892) and daptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity. J. Antimicrob. Chemother. (1990) 26:491–501.
   PubMed Web of Science ®Google Scholar
• OLIVER N, ANDREW T, SILVERMAN JA, LI T: In vitro studies on resistance to the lipopeptide antibiotic daptomycin. Program and Abstracts of the 38th InterscE ence Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (1998). Abstract F–117.
   Google Scholar
• •Daptomycin exhibits a very low rate of resistance in vitro.
   Google Scholar
• KAATZ GW, SEO SM, LUNDSTROM TS: Development of daptomycin resistance (Di) in experimental Staphylo-coccus aureus (SA) endocarditis. Program and Abstracts of the 33rd Intel-science Conference on Antimicrobial Agents and Chemotherapy (1993). Abstract 155.
   Google Scholar
• DATA ON FILE: Adams, and Van Rosenstiel, Eli Lilly and Company, IND No. 27,627: 13,337.
   Google Scholar
• DATA ON FILE: IND No. 57,693, Table 10.21, Cubist Pharmaceuticals, Inc.
   Google Scholar
• SMITH K, COBBS G, DILL R, LYON D, GRAVES A, AVENT K: Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model. Chemotherapy (1990) 36:428–434.
   PubMed Web of Science ®Google Scholar
• DATA ON FILE: In vivo models. Cubist Pharmaceuticals, Inc., IND No. 57,693.
   Google Scholar
• NORD CE, LINDMARK A, PERSSON I: LY146032 treatment of Clostridium difficile colitis in hamsters. Eur. J. Clin. Microbiol. Infect. Dis. (1987) 6:686.
   Web of Science ®Google Scholar
• BUSH LM, BOSCIA JA, KAYE D: Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob. Agents Chemother. (1988) 32:877–881.
   PubMed Web of Science ®Google Scholar
• ••Daptomycin effectiveness in an animal model ofendocarditis.
   Google Scholar
• CANTONI L, GLAUSER MP, BILLE J: Comparative efficacy of daptomycin, vancomycin and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob. Agents Chemother. (1990) 34:2348–2353.
   PubMed Web of Science ®Google Scholar
• ••Daptomycin efficacy against S. aureus-induced endocar-ditis in rats.
   Google Scholar
• CARON F, KITZIS M-D, GUTMANN L et al Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob. Agents Chemother. (1992) 36:2611–2616.
   PubMed Web of Science ®Google Scholar
• ••Daptomycin effectiveness against VRE-induced experi-mental endocarditis.
   Google Scholar
• HINDES RG, WILLEY SH, ELIOPOULOS GM et al: Treatment of experimental endocarditis caused by I3-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob. Agents Chemother. (1989) 33:1019–1022.
   PubMed Web of Science ®Google Scholar
• KAATZ GW, SEO SM, REDDY VN, BAILEY EM, RYBAK MJ: Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylo-coccus aureus endocarditis. Antimicrob. Agents Chemother. (1990) 34:2081–2085.
   PubMed Web of Science ®Google Scholar
• KENNEDY S, CHAMBERS HF: Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob. Agents Chemother. (1989) 33:1522–1525.
   PubMed Web of Science ®Google Scholar
• LEGGETT J, TOTSUKA K, EBERT S, VOGELMAN B, CRAIGWA: Pharmacodynamic and pharmacokinetic parame-ters (PKPs) affecting activity of LY 146032 against Staphylococcus aureus. Program and Abstracts of the 27th Intel-science Conference on Antimicrobial Agents and Chemotherapy. New York, USA (1987).
   Google Scholar
• •Daptomycin's Cm, or AUC-driven efficacy in an animal model of thigh infection.
   Google Scholar
• MINITER PM, PATTERSON TF, JOHNSON MA, ANDRIOLE VT: Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob. Agents Chemother. (1987) 31:1199–1203.
   PubMed Web of Science ®Google Scholar
• SAPICO FL, GINUNAS VJ, CANAWATI HN, MONTGOMERIE JZ: LY146032, alone and in combina-tion with gentamicin, for the treatment of entero-coccal pyelonephritis in the rat model. Antimicrob. Agents Chemother. (1988) 32:81–83.
   PubMed Web of Science ®Google Scholar
• MADER JT, ADAMS K: Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob. Agents Chemother. (1989) 33:689–692.
   PubMed Web of Science ®Google Scholar
• LUU QN, BUXTON TB, NELSON DR, RISSING JP: Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur. j Clin. Microbiol. Infect. Dis. (1989) 8:562–563.
   PubMed Web of Science ®Google Scholar
• DONG M-Y, CHANG T-W, GORBACH SL: Treatment ofClostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032. Antimicrob. Agents Chemother. (1987) 31:1135–1136.
   PubMed Web of Science ®Google Scholar
• KEPHART PA, ESPOSITO AL: Comparison of the investi-gational drug, LY146032, with vancomycin in experi-mental pneumonia due to methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (1988) 21:33–39.
   PubMed Web of Science ®Google Scholar
• VERGHESE A, HAIRE C, FRANZUS B, SMITH K: LY146032in a hamster model of Staphylococcus aureus pneumonia-effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy (1988) 34:497–503.
   PubMed Web of Science ®Google Scholar
• RAMOS MC, GRAYSON ML, ELIOPOULOS GM, BAYER AS: Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant entero-cocci. Antimicrob. Agents Chemother. (1992) 36:1864–1869.
   PubMed Web of Science ®Google Scholar
• OLESON FB, JR, BERMAN CL, KIRKPATRICK JB, REGAN KS, LAI J-J, TALLY FP: Once-daily dosing decreases toxicity of daptomycin. Toxicol. ScL (1999) 48:322.
   Google Scholar
• •Daptomycin's myotoxicity is dependent on dosing frequency.
   Google Scholar
• LEE BL, SACHDEVA M, CHAMBERS HF: Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. (1991) 35:2505–2508.
   PubMed Web of Science ®Google Scholar
• WOODWORTH JR, NYHART EH, BRIER GL, WOLNY JD, BLACK HR: Single-dose pharmacokinetics and antibac-terial activity of daptomycin, a new lipopeptide antibi-otic, in healthy volunteers. Antimicrob. Agents Chemother. (1992) 36:318–325.
   PubMed Web of Science ®Google Scholar
• ••Clinical pharmacokinetic profile of daptomycin at singledoses up to 6 mg/kg.
   Google Scholar
• DATA ON FILE: Study B8B-LC-AVAC. Cubist Pharmaceuti-cals, Inc.
   Google Scholar
• DATA ON FILE: Study B8B-LC-AVAJ. Cubist Pharmaceuti- cals, Inc.
   Google Scholar
• DATA ON FILE: Study B8B-EW-0001. Cubist Pharmaceuti-cals, Inc.
   Google Scholar
• ROWLAND M, TOZER TN: In: Clinical Pharmacokinetics: Concepts and Applications (3rd edition) Williams & Wilkins, Baltimore, MD, USA (1995):272–273.
   Google Scholar
• DATA ON FILE: Study B8B-MC-AVAE. Cubist Pharmaceuti-cals, Inc.
   Google Scholar
• DATA ON FILE: Study B8B-MC-AVAM. Cubist Pharmaceu-ticals, Inc.
   Google Scholar
• DATA ON FILE: Study B8B-MC-AVAG. Cubist Pharmaceuti-cals, Inc.
   Google Scholar
• WOODWORTH JR, NYHART EH, WOLNY JD, BRIER GL, BLACK HR: Tobramycin and daptomycin disposition when co-administered to healthy volunteers. J. Antimi-crob. Chemother. (1994) 33:655–659.
   PubMed Web of Science ®Google Scholar
• COUTURE M, SIMARD M, GOURDE P et al.: Daptomycin may attenuate experimental tobramycin nephrotox-icity by electrostatic complexation to tobramycin. Antimicrob. Agents Chemother. (1994) 38:742–749.
   PubMed Web of Science ®Google Scholar
• KREFT B, DE WIT C, KRECH R, MARRE R, SCHULZE E, SACK K: Experimental studies on nephrotoxicity and pharmacokinetics of LY 146032 (daptomycin) in rats. J. Antimicrob. Chemother. (1990) 25:635–643.
   PubMed Web of Science ®Google Scholar
• THIBAULT N, GRENIER L, SIMARD M, BERGERON MG, BEAUCHAMP D: Protection against gentamicin nephro-toxicity by daptomycin in nephrectomized rats. Life ScL (1995) 56:1877–1887.
   PubMed Web of Science ®Google Scholar
• THIBAULT N, GRENIER L, SIMARD M, BERGERON MG, BEAUCHAMP D: Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob. Agents Chemother. (1994) 38:1027–1035.
   PubMed Web of Science ®Google Scholar
• BEAUCHAMP D, PELLERIN M, GOURDE P, PETTIGREW M, BERGERON MG: Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob. Agents Chemother. (1990) 34:139–147.
   PubMed Web of Science ®Google Scholar
• WOOD CA, FINKBEINER HC, KOHLHEPP SJ, KOHNEN PW, GILBERT DN: Influence of daptomycin on staphy-lococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob. Agents Chemother. (1989) 33:1280–1285.
   PubMed Web of Science ®Google Scholar
• DATA ON FILE: Study B8B-MC-AVAP. Cubist Pharmaceuti-cals, Inc.
   Google Scholar
• DATA ON FILE: LI TC et al, Cubist Pharmaceuticals, Inc.
   Google Scholar
• DATA ON FILE: IND No. 57,693, Table 8.7, Cubist Pharma-ceuticals, Inc.
   Google Scholar